Treatment of Nuclear Medicine-Confirmed Thyroiditis

Introduction to Thyroiditis Treatment

The treatment for nuclear medicine-confirmed thyroiditis should be symptom-directed, with beta blockers for symptomatic relief during the thyrotoxic phase and close monitoring for transition to hypothyroidism, which may require thyroid hormone replacement therapy, as recommended by the Journal for ImmunoTherapy of Cancer and Journal of Clinical Oncology 1, 2

Beta blockers (e.g., atenolol or propranolol) should be used for symptomatic relief of adrenergic symptoms such as palpitations, tremors, and anxiety, according to the Journal of Clinical Oncology 2
Monitor thyroid function every 2-3 weeks to detect transition to hypothyroidism, as suggested by the Journal of Clinical Oncology 2
Continue immune checkpoint inhibitor therapy for mild symptoms if thyroiditis is related to immunotherapy, as recommended by the Journal of Clinical Oncology 2

Consider levothyroxine therapy for patients with TSH > 10 mIU/L or TSH 4-10 mIU/L with symptoms, as suggested by the Journal of Clinical Oncology 2

For severe symptoms (Grade 3-4) affecting daily activities, consider hospitalization, endocrinology consultation, and more aggressive hydration and supportive care, according to the Journal of Clinical Oncology 2
Thyroiditis is a common immune-related adverse event in patients receiving immune checkpoint inhibitors, and treatment approach is similar but may require endocrinology consultation for persistent thyrotoxicosis (>6 weeks), as reported by the Journal for ImmunoTherapy of Cancer and Journal of Clinical Oncology 1, 2, 3
Permanent hypothyroidism is more common in cases of immunotherapy-related thyroiditis, as noted by the Journal for ImmunoTherapy of Cancer 3
If thyrotoxic phase persists beyond 6 weeks, consider endocrinology consultation, additional workup to rule out Graves' disease, and possible medical thyroid suppression, as recommended by the Journal of Clinical Oncology 2
It is essential to monitor for changes in thyroid function and adjust treatment accordingly to avoid missing the transition from hyperthyroidism to hypothyroidism, as emphasized by the Journal of Clinical Oncology 2